Replimune's skin cancer drug is rejected again by the US FDA, causing the company's stock price to plummet
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Michael Saylor's Bitcoin Treasury Secures Nearly $1 Billion in Profit
Why Is SpaceX Stock Price Down Today?
Strong demand for Wegovy oral tablets drives Novo Nordisk (NVO.US) Q3 revenue and profit to surpass expectations, with annual performance guidance raised again.
Novo Nordisk released its financial report for the first three quarters of 2026 on November 4.
JPMorgan maintains “Overweight” rating on Unilever (UL.US): The new mid-term framework strengthens growth quality, and high single-digit EPS growth is expected to drive revaluation.
JPMorgan released a research report, maintaining an "Overweight" rating for Unilever and setting its European stock target price at 65 euros and its UK stock target price at 5,700 pence.
Crypto prices
More
